Global Genetic Testing Market – Industry Analysis And Market Forecast (2016 - 2021) - Product Image

Global Genetic Testing Market – Industry Analysis And Market Forecast (2016 - 2021)

  • ID: 2878218
  • Report
  • Region: Global
  • 139 Pages
  • Mordor Intelligence
1 of 5

FEATURED COMPANIES

  • Abbott Molecular
  • Biocartis Sa
  • Cepheid
  • Genomictree, Inc.
  • Luminex Corporation
  • Natera, Inc.
  • MORE
Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues.

Genetic Testing market growth is driven by increasing adoption of oncology applications, growing public awareness and demand for personalized medicine. It advances with aging population and a subsequent rise in the number of chronic diseases, and increasing incidence of cancer cases are the other factors propelling growth in the genetic testing market.

Genetic testing represents the most rapidly expanding segment of the molecular diagnostics market worldwide. Growing incidence of genetic diseases unravels new opportunities for genetic testing. The transformation of genetic testing from being a service-driven market to a product-driven market is expected to provide an impetus to the diagnostic companies for the expansion of their operations.
Genetic Testing market sales are expected to reach $25 billion annually by 2021 with compound annual growth rate of 10% alone in United States. The Global genetic testing market is expected to reach approximately $60 billion by 2020. The US represents the largest market for genetic testing worldwide.

Genetic testing not only identifies the finest cancer treatment for specific patients, but also permits physicians to find if some drugs are unsuitable for a section of patients, while they can be given freely to a majority of others.

This report provides the Genetic Testing Market Forecasting Model, offers valuable insights on global evolution, regional variation, and current market trends. The report also provides Company Profiles with Pipeline Products and financials.

Major players profiled in the report include Abbott Diagnostics, Biocartis SA, bioMerieux S.A., Celera Group, Cepheid, EKF Diagnostics Holdings plc, Genentech, Inc., IntegraGen S.A, Luminex Corporation, Qiagen N.V., Roche Diagnostics Limited, Seegene, Inc., Transgenomic, Inc., among others.

Scope:

- Global Market evolution, strategic assessment of Indications market impact analysis, future market and company analysis
- Competitive Assessment including Pipeline Product approval analysis
- Coverage of Major Players includes company profiles, financials and major products and services.

Countries Covered:

- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Mexico
- Spain
- USA
- United Kingdom
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Molecular
  • Biocartis Sa
  • Cepheid
  • Genomictree, Inc.
  • Luminex Corporation
  • Natera, Inc.
  • MORE
1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 RESEARCH METHODOLOGY

2 GENETIC TESTING MARKET OVERVIEW
2.1 GLOBAL GENETIC TESTING INTRODUCTION
2.1.1 Cells and DNA
2.1.2 Gene Families
2.1.3 Gene Mutations
2.1.4 Gene Inheritance
2.1.5 Genetic Consultation

3 GLOBAL GENETIC TESTING – MARKET FORCES
3.1 MARKET DRIVERS
3.1.1 Increase of Pipeline Genetic Tests
3.1.2 Early Confirmation of Genetic Disorders
3.1.3 Minimal Procedure Risk
3.1.4 Guide Strategies for Maintaining Health
3.1.5 Guide Treatment Choices for a variety of Disease Conditions
3.2 MARKET RESTRAINTS
3.2.1 False-Positive and False-Negative Results
3.2.2 Potential Adverse Personal or Societal Consequences
3.2.3 Non-inclusion of Reimbursement Policy
3.3 OPPORTUNITIES
3.3.1 Genetic Counseling

4 GLOBAL GENETIC TESTING MARKET, BY TYPES
4.1 OVERVIEW
4.1.1 Global Genetic Testing Market, By Types, 2014-2020
4.2 CARRIER TESTING
4.2.1 Global Carrier Testing Market, 2014-2020
4.3 DIAGNOSTIC TESTING
4.3.1 Global Diagnostic Testing Market, 2014-2020
4.4 NEWBORN SCREENING
4.4.1 Global Newborn Screening Market, 2014-2020
4.5 PREDICTIVE AND PRESYMPTOMATIC TESTING
4.5.1 Global Predictive and Presymptomatic Testing Market, 2014-2020
4.6 PRENATAL TESTING
4.6.1 Global Prenatal Testing Market, 2014-2020

5 GENETIC TESTING MARKET, BY GEOGRAPHY
5.1 OVERVIEW
5.1.1 Global Genetic Testing Market, by Geography, 2014-2020
5.2 NORTH AMERICA
5.2.1 North America Genetic Testing Market, 2014-2020
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.3 EUROPE
5.3.1 Europe Genetic Testing Market, 2014-2020
5.3.1.1 France
5.3.1.2 Germany
5.3.1.3 Italy
5.3.1.4 Spain
5.3.1.5 United Kingdom
5.3.1.6 Rest of Europe
5.4 ASIA-PACIFIC
5.4.1 Asia-Pacific Genetic Testing Market, 2014-2020
5.4.1.1 China
5.4.1.2 India
5.4.1.3 Japan
5.4.1.4 Rest of Asia-Pacific
5.5 REST OF THE WORLD
5.5.1 Rest of the World Genetic Testing Market, by Type, 2014-2020

6 COMPETITIVE LANDSCAPE

7 COMPANY PROFILES
7.1 23ANDME, INC.
7.1.1 Overview
7.1.2 Major Products and Services
7.1.3 Genetic Testing Pipeline Products
7.1.4 Financials
7.1.5 Developments
7.2 ABBOTT MOLECULAR
7.2.1 Overview
7.2.2 Major Products and Services
7.2.3 Genetic Testing Pipeline Products
7.2.4 Financials
7.2.5 Developments
7.3 ARIOSA DIAGNOSTICS, Inc
7.3.1 Overview
7.3.2 Major Products and Services
7.3.3 Genetic Testing Pipeline Products
7.4 BIOCARTIS SA
7.4.1 Overview
7.4.2 Major Products and Services
7.4.3 Genetic Testing Pipeline Products
7.4.4 Financials
7.4.5 Developments
7.5 BIOHELIX CORPORATION (Wholly Owned Subsidiary of Quidel)
7.5.1 Overview
7.5.2 Major Products and Services
7.5.3 Genetic Testing Pipeline Products
7.5.4 Financials
7.5.5 Developments
7.6 BIOMERIEUX S.A.
7.6.1 Overview
7.6.2 Major Products and Services
7.6.3 Genetic Testing Pipeline Products
7.6.4 Financials
7.6.5 Developments
7.7 CELERA CORPORATION
7.7.1 Overview
7.7.2 Major Products and Services
7.7.3 Genetic Testing Pipeline Products
7.7.4 Financials
7.7.5 Developments
7.8 CEPHEID
7.8.1 Overview
7.8.2 Major Products and Services
7.8.3 Financials
7.8.4 Developments
7.9 DAAN DIAGNOSTICS LTD.
7.9.1 Overview
7.9.2 Major Products and Services
7.9.3 Genetic Testing Pipeline Products
7.9.4 Financials
7.10 EKF DIAGNOSTICS HOLDINGS PLC
7.10.1 Overview
7.10.2 Major Products and Services
7.10.3 Financials
7.10.4 Developments
7.11 GENENTECH, INC.
7.11.1 Overview
7.11.2 Genetic Testing Pipeline Products
7.11.3 Financials
7.11.4 Developments
7.12 GENOMICTREE, INC.
7.12.1 Overview
7.12.2 Major Products and Services
7.12.3 Genetic Testing Pipeline Products
7.12.4 Financials
7.12.5 Developments
7.13 HTG MOLECULAR DIAGNOSTICS, INC.
7.13.1 Overview
7.13.2 Major Products and Services
7.13.3 Genetic Testing Pipeline Products
7.13.4 Financials
7.13.5 Developments
7.14 ILLUMINA, INC
7.14.1 Overview
7.14.2 Major Products and Services
7.14.3 Financials
7.14.4 Developments
7.15 INTEGRAGEN S.A
7. 15.1 Overview
7. 15.2 Major Products and Services
7. 15.3 Financials
7. 15.4 Developments
7.16 LABORATORY CORPORATION OF AMERICA HOLDINGS
7.16.1 Overview
7.16.2 Major Products and Services
7.16.3 Financials
7.16.4 Developments
7.17 LUMINEX CORPORATION
7.17.1 Overview
7.17.2 Major Products and Services
7.17.3 Genetic Testing Pipeline Products
7.17.4 Financials
7.17.5 Developments
7.18 MOLECULARMD, CORP.
7.18.1 Overview
7.18.2 Major Products and Services
7.18.3 Financials
7.18.4 Developments
7.19 MYRIAD GENETICS, INC.
7.19.1 Overview
7.19.2 Major Products and Services
7.19.3 Genetic Testing Pipeline Products
7.19.4 Financials
7.19.5 Developments
7.20 NATERA, INC.
7.20.1 Overview
7.20.2 Major Products and Services
7.20.3 Developments
7.21 OXFORD BIODYNAMICS LIMITED
7.21.1 Overview
7.21.2 Major Products and Services
7.21.3 Genetic Testing Pipeline Products
7.21.4 Financials
7.21.5 Developments
7.22 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
7.22.1 Overview
7.22.2 Major Products and Services
7.22.3 Financials
7.22.4 Developments
7.23 PERKINELMER, INC.
7.23.1 Overview
7.24 QIAGEN N.V.
7.24.1 Overview
7.24.2 Major Products and Services
7.24.3 Genetic Testing Pipeline Products
7.24.4 Financials
7.24.5 Developments
7.25 ROCHE DIAGNOSTICS LIMITED
7.25.1 Overview
7.25.2 Major Products and Services
7.25.3 Financials
7.25.4 Developments
7.26 SEEGENE, INC.
7.26.1 Overview
7.26.2 Financials
7.26.3 Developments
7.27 SEQUENOM, INC.
7.27.1 Overview
7.27.2 Major Products and Services
7.27.3 Financials
7.27.4 Developments
7.28 SIEMENS HEALTHCARE
7.28.1 Overview
7.28.2 Major Products and Services
7.28.3 Financials
7.28.4 Developments
7.29 TRANSGENOMIC, INC.
7.29.1 Overview
7.29.2 Major Products and Services
7.29.3 Genetic Testing Pipeline Products
7.29.4 Financials
7.29.5 Developments

8 DISCLAIMER
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Andme, Inc.
- Abbott Molecular
- Ariosa Diagnostics, Inc
- Biocartis Sa
- Biohelix Corporation (Wholly Owned Subsidiary Of Quidel)
- Biomerieux S.A.
- Celera Corporation
- Cepheid
- Daan Diagnostics Ltd.
- Ekf Diagnostics Holdings Plc
- Genentech, Inc.
- Genomictree, Inc.
- Htg Molecular Diagnostics, Inc.
- Illumina, Inc
- Integragen S.A
- Laboratory Corporation Of America Holdings
- Luminex Corporation
- Molecularmd, Corp.
- Myriad Genetics, Inc.
- Natera, Inc.
- Oxford Biodynamics Limited
- Pacific Biosciences Of California, Inc.
- Perkinelmer, Inc.
- Qiagen N.V.
- Roche Diagnostics Limited
- Seegene, Inc.
- Sequenom, Inc.
- Siemens Healthcare
- Transgenomic, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll